Victoza

Victoza

liraglutide

Manufacturer:

Novo Nordisk

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Liraglutide
Indications/Uses
Adjunct to diet & exercise for the treatment of adults w/ insufficiently controlled type 2 DM as monotherapy when metformin is inappropriate; or in addition to other medicinal products for diabetes. Adjunct to diet, exercise & standard care therapy to reduce risk of major CV events in patients w/ type 2 DM & established CV disease who have inadequate glycaemic control.
Dosage/Direction for Use
SC Initially 0.6 mg daily, increased to 1.2 mg after at least 1 wk. Max: 1.8 mg daily. No dose adjustment is required during Ramadan when added to metformin; recommended to finalize dose escalation before patients start Ramadan fasting.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Not to be administered IV or IM. Not a substitute for insulin. Do not use in patients w/ type 1 DM or for treatment of diabetic ketoacidosis. Not recommended in patients w/ CHF NYHA class IV; inflammatory bowel disease & diabetic gastroparesis. Discontinue use if pancreatitis is suspected, & do not restart if acute pancreatitis is confirmed. Patients w/ pre-existing thyroid disease. May increase risk of hypoglycaemia, in combination therapy w/ a sulphonylurea or insulin. Potential risk of dehydration in relation to GI side effects. Not recommended in patients w/ end-stage renal disease & severe hepatic impairment. May affect ability to drive & use machines in case of hypoglycaemia. Do not use during pregnancy & lactation. Childn & adolescent <18 yr.
Adverse Reactions
Nausea, diarrhoea. Nasopharyngitis, bronchitis; hypoglycaemia, anorexia, decreased appetite; headache, dizziness; increased heart rate; vomiting, dyspepsia, upper abdominal pain, constipation, gastritis, flatulence, abdominal distention, GERD, abdominal discomfort, toothache eructation; rash; fatigue, inj site reactions; increased lipase & amylase.
Drug Interactions
Frequent monitoring of INR in patients on warfarin & other coumarin derivatives.
MIMS Class
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Victoza soln for inj 6 mg/mL
Packing/Price
3 mL x 2 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in